Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 6/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6272728 | 0.90 | PNP (0.58) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL5935062 | 0.90 | PNP (0.70) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL8522269 | 0.89 | PNP (0.56) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL6272296 | 0.88 | PNP (0.54) | PNP | |
| SCHEMBL7777164 | 0.88 | PNP (0.54) | PNP | |
| SCHEMBL8536005 | 0.88 | PNP (0.54) | PNP | |
| Hydrochloric Acid SCHEMBL258896 | 0.86 | PNP (0.53) | PNP | |
| SCHEMBL874735 | 0.86 | PNP (0.66) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL9806967 | 0.85 | PNP (0.63) | PNPKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL441796 | 0.83 | PNP (0.61) | PNPKDM4EMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026106956-A1 | DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | MODERNATX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | ADVANCED RNA VACCINE ARV TECH INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | MODERNATX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | MODERNATX, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4727955-A1 | CYSTEINE-SUBSTITUTED RSV-F PROTEINS | GlaxoSmithKline Biologicals S.A. (BE) | 2026-04-22 | — | — | EP | disclosed |
| EP-3458081-B1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | MODERNATX INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260097110-A1 | BETACORONAVIRUS mRNA VACCINES | MODERNATX, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260091104-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2026-04-02 | — | — | US | disclosed |
| EP-2451823-A2 | COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION OF A BIOLOGICAL PRODUCT | Alnylam Pharmaceuticals, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2451940-A1 | BIOPROCESSING | Alnylam Pharmaceuticals, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2451476-A1 | CELL-BASED BIOPROCESSING | Alnylam Pharmaceuticals, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120046346-A1 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | IMMUNE DISEASE INSTITUTE, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2009155504-A9 | METHODS FOR THE MODULATION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009155504-A2 | METHODS FOR THE MODULATION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009149239-A1 | METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-12-10 | — | — | WO | disclosed |
| EP-1017394-B1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER REC TECH LTD (GB) | 2005-12-07 | — | — | EP | disclosed |
| US-6303618-B1 | ADMINISTERING PURINE COMPOUND WHICH INHIBITS CYCLIC DEPENDENT KINASE ACTIVITY FOR THERAPY OF TUMOR OR OTHER CELL PROLIFERATION DISORDER | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2001-10-16 | — | — | US | disclosed |
| WO-1999002162-A9 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RES CAMPAIGN TECH (GB) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097110-A1 | BETACORONAVIRUS mRNA VACCINES | RNMT, RNGTT, METTL16 | PNP 37/4885KDM4E 1943/4885MEN1 2458/4885 |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | RNGTT, CDA, DCTD | PNP 14/4885KDM4E 3277/4885MEN1 4354/4885 |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | RNMT, RNGTT, METTL16 | PNP 36/4885KDM4E 1991/4885MEN1 2103/4885 |
| US-20260091104-A1 | NUCLEIC ACID VACCINES | RNMT, NSUN2, AMPD1 | PNP 14/4885KDM4E 1239/4885MEN1 1835/4885 |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | RNMT, METTL16, NSUN2 | PNP 317/4885KDM4E 2008/4885MEN1 2371/4885 |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | NSUN2, RNMT, RNGTT | PNP 361/4885KDM4E 260/4885MEN1 3114/4885 |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | UPF1, NSUN2, CD4 | PNP 460/4885KDM4E 1144/4885MEN1 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.